Want to join the conversation?
$CSRA said beginning in FY17, it intends to provide guidance for annual periods rather than quarters, since the timing of the spin-off transaction was not conducive to that approach in FY16. $CSRA expects 4Q16 revenue in the range of $1.28-1.33Bil. Adjusted EBITDA is expected to be $214-226MM and adjusted diluted EPS to be $0.45-0.49 in 4Q16.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.